SCO-267 is under development for the treatment of non-alcoholic steatohepatitis (NASH), diabetes, nonalcoholic fatty liver disease and obesity. It acts by targeting GPR40. It is administered through ...
By Jamie Mayes Click here for updates on this story SALEM, Indiana (WLKY) — On Christmas morning, while many children eagerly anticipate unwrapping the latest toys and gadgets. Seth Heninger is ...